Sex differences in the drug therapy for oncologic diseases

Handbook of Experimental Pharmacology

Volumn 214, Issue , 2012, Pages 411-442

  Schmetzer, Oliver ^a,b   Flörcken, Anne ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytostatic therapy; Drug; Gender; Half life; Metabolism

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2A6; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GLUTATHIONE TRANSFERASE; GROWTH FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; MONOCLONAL ANTIBODY; MORPHINE; PACLITAXEL; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TENIPOSIDE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VINCA ALKALOID; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; EWING SARCOMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; GENE; GENE EXPRESSION REGULATION; GENE LOCATION; HAND FOOT SYNDROME; HEART; HNF3BETA GENE; HNF4ALPHA GENE; HODGKIN DISEASE; HUMAN; INFECTION; KIDNEY; LIVER; LIVER METABOLISM; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MUCOSAL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSITIS; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN TOXICITY; STAT5B GENE; TISSUE DISTRIBUTION; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM; NEOPLASM; REVIEW; SEXUAL DEVELOPMENT;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIVER; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SEX CHARACTERISTICS;

EID: 84868307423     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-30726-3_19     Document Type: Article

References (153)

1. (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16(11): 3537-3541
2. Anderson GD (2005) Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 14(1):19-29
3. Aziz Z, Iqbal J et al (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52(6):1017-1023
4. Benet LZ, Cummins CL et al (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277(1-2):3-9
5. Bennett E, McGuinness L et al (2005) Hypothalamic STAT proteins: regulation of somatostatin neurones by growth hormone via STAT5b. J Neuroendocrinol 17(3):186-194
6. Bjorkholm M, Ohm L et al (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29 (18):2514-2520
7. Blain PG, Mucklow JC et al (1985) Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol 20(5):500-502
8. Brahmer JR, Dahlberg SE et al (2011) Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol 6(1):103-108
9. Burns JW, Hodsman NB et al (1989) The influence of patient characteristics on the requirements for postoperative analgesia. A reassessment using patient-controlled analgesia. Anaesthesia 44(1):2-6
10. Cartron G, Trappe RU et al (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 17(1):19-30
11. Cepeda MS, Farrar JT et al (2003) Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 74(2):102-112
12. Chansky K, Benedetti J et al (2005) Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103(6):1165-1171
13. Chia YY, Chow LH et al (2002) Gender and pain upon movement are associated with the requirements for postoperative patient-controlled iv analgesia: a prospective survey of 2,298 Chinese patients. Can J Anaesth 49(3):249-255
14. Cho HJ, Eom HS et al (2010) Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet 198(1):40-46
15. Ciardiello FTG (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
16. Clodfelter KH, Holloway MG et al (2006) Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol 20(6):1333-1351
17. Dahan A, Sarton E et al (1998) Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology 88(4):903-913
18. Dahlstrom B, Tamsen A et al (1982) Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 7(3):266-279
19. Davis M (2005) Gender differences in p-glycoprotein: drug toxicity and response. J Clin Oncol 23(26):6439-6440
20. Dobbs NA, Twelves CJ et al (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36(6):473-476
21. Dooley MJ, Poole SG et al (2002) Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 38(1):44-51
22. Ebert SN, Liu XK et al (1998) Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 7(5):547-557
23. Ell K, Nishimoto R et al (1992) Social relations, social support and survival among patients with cancer. J Psychosom Res 36(6):531-541
24. Escudier B, Eisen T et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134
25. Fang Y, Li LJ et al (2010) Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. Acta Pharmacol Sin 31(11):1500-1507
26. Farker K, Merkel U et al (2006) Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. Int J Clin Pharmacol Ther 44(1):31-37
27. Flores-Morales A, Stahlberg N et al (2001) Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology 142(7):3163-3176
28. Franconi F, Brunelleschi S et al (2007) Gender differences in drug responses. Pharmacol Res 55(2):81-95
29. Friedman CJ, Burris HA 3rd et al (2000) Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist 5(2):136-143
30. Fukuoka MYS, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small lung cancer. J Clin Oncol 21:2237-2246
31. Gear RW, Miaskowski C et al (1996) Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 2(11):1248-1250
32. Gill S, Loprinzi CL et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22(10):1797-1806
33. Gleiter CH, Gundert-Remy U (1996) Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 21(2):123-128
34. Gralla RJ, Osoba D et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971-2994
35. Gusella M, Crepaldi G et al (2006) Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol 17(11):1656-1660
36. Halm U, Schumann T et al (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82(5):1013-1016
37. Han JY, Lim HS et al (2006) Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 106(4):873-880
38. Hansen NL, Chandiramani D, Morse MA, Wei D, Hedrick NE, Hansen RA (2011) Incidence and predictors oc cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract 17:125-130
39. Harichand-Herdt S, Ramalingam SS (2009) Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin Oncol 36(6):572-580
40. Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30(6):445-600
41. Heiss GWA, Anderson GL, Aragaki A, Beresford SA, Brzysk R et al (2008) Helath risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036-1045
42. Hempel G, Flege S et al (2002) Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 49(2):133-141
43. Herrington J, Carter-Su C (2001) Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 12(6):252-257
44. Hesketh PJ, Grunberg SM et al (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14(4):354-360
45. Higashi E, Fukami T et al (2007a) Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35(10):1935-1941
46. Higashi E, Nakajima M et al (2007b) Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos 35(4):508-514
47. Hoensch H, Morgenstern I et al (2002) Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut 50(2):235-240
48. Horie N, Aiba H et al (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20(3):191-197
49. Howie AF, Forrester LM et al (1990) Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 11(3):451-458
50. Huang HJ, Tsai ML et al (2011) Quantitative shot-gun proteomics and MS-based activity assay for revealing gender differences in enzyme contents for rat liver microsome. J Proteomics 74(12):2734-2744
51. Huyghe E, Zairi A et al (2007) Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 20(4):305-311
52. Inagaki K, Inagaki M et al (2002) A wide interindividual variability of urinary 6beta-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition. Ther Drug Monit 24(6):722-727
53. Jann MW, ZumBrunnen TL et al (1998) Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 18(2):288-294
54. Jansman FG, Sleijfer DT et al (2000) Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23(4):255-278
55. Jansson JO, Ekberg S et al (1985) Imprinting of growth hormone secretion, body growth, and hepatic steroid metabolism by neonatal testosterone. Endocrinology 117(5):1881-1889
56. Joerger M, Huitema AD et al (2006) Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 12(7 Pt 1):2150-2157
57. Juergens C, Weston C et al (2006) Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47(1):22-29
58. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 93(11):5512-5516
59. Kajita J, Kuwabara T et al (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28(9):1121-1127
60. Kaminski A, Joseph D et al (2007) Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. Australas Radiol 51(3):283-288
61. Khamly KK, Thursfield VJ et al (2009) Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer 125(2):426-431
62. Kim Y, Morrow GR (2003) Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 11(3):171-177
63. Klimm B, Reineke T et al (2005) Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 23(31):8003-8011
64. Kris MG, Natale R, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small lung cancer. JAMA 290:2149-2158
65. Lamba V, Lamba J et al (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307(3):906-922
66. Lambert LA, Armstrong TS et al (2009) Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181-2187
67. Lavoie JC, Chessex P (1997) Gender and maturation affect glutathione status in human neonatal tissues. Free Radic Biol Med 23(4):648-657
68. Lee YT, Chan KK et al (1980) Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer 45(9):2231-2239
69. Lee JP, Birnstein E et al (2009) Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol 2:30
70. Leveque D, Wisniewski S et al (2005) Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res 25(3c):2327-2343
71. Liaw CC, Wang CH et al (2001) Gender discrepancy observed between chemotherapy-induced emesis and hiccups. Support Care Cancer 9(6):435-441
72. Liaw CC, Chang HK et al (2003) Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol 26(1):12-15
73. Llovet JM, Ricci S et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
74. Lu JF, Bruno R et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62(5):779-786
75. Mader RM (2006) Gender specific tumour pharmacology-from kinetics to genetics. Wien Med Wochenschr 156(19-20):545-548
76. Mader RM, Steger GG et al (1995) Stereospecific pharmacokinetics of rac-5-methyltetrahy-drofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol 40(3):209-215
77. Maki RG, Keohan ML, Undevia SD, Livingston M, Cooney MM, Elias A, Saulle MF, Wright JJ, D'Adamo DR, Schuetze SM (2008) Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. J Clin Oncol 26(15):10531
78. Marosi C (2006) Gender aspects of treatment and drug related toxicity in medical oncology. Wien Med Wochenschr 156(19-20):534-540
79. Marre F, Sanderink GJ et al (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296-1302
80. Milano G, Etienne MC et al (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10(7):1171-1175
81. Miners JO, Attwood J et al (1983) Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16(5):503-509
82. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26(4):292-307
83. Motzer RJ, Hutson TE et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124
84. Motzer RJ, Hutson TE et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584-3590
85. Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10(1):84-96
86. Mulder TP, Court DA et al (1999) Variability of glutathione S-transferase alpha in human liver and plasma. Clin Chem 45(3):355-359
87. Nestorov I, Zitnik R et al (2004) Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 31(6):463-490
88. Ng CM, Bruno R et al (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45 (7):792-801
89. Nussler NC, Reinbacher K et al (2008) Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med 5(3):209-217
90. O'Connell JP, Kris MG et al (1986) Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4(11):1604-1614
91. Ober RJ, Radu CG et al (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13(12):1551-1559
92. Osoba D, Zee B et al (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116-123
93. Paez JG, Janne P, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
94. Peng B, Lloyd P et al (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879-894
95. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-samll lung cancer. J Clin Oncol 22:3238-3247
96. Petru E, Andel J et al (2008) Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wien Med Wochenschr 158(5-6):169-173
97. Pfreundschuh M, Murawski N, Zeynalova S et al (2009) Male sex is associated with lower rituximab trough serum levels and evolves as a significant prognostic factor in elderly patients with DLBCL treated with R-CHOP: results from 4 prospective trials of the German HighGrade Non-Hodgkin-Lymphoma Study Group (DSHNHL). Blood 114:3715a
98. Pleym H, Spigset O et al (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47(3):241-259
99. Puisset F, Dalenc F et al (2005) Dexamethasone as a probe for vinorelbine clearance. Br J Clin Pharmacol 60(1):45-53
100. Puisset F, Chatelut E et al (2007) Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol 60(2):305-308
101. Ramani VS, Gollins SW et al (2006) Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. Clin Oncol (R Coll Radiol) 18(9):649-657
102. Reynolds P, Kaplan GA (1990) Social connections and risk for cancer: prospective evidence from the Alameda County Study. Behav Med 16(3):101-110
103. Riihijarvi S, Taskinen M et al (2011) Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 86(2):124-128
104. Rini BI, Escudier B et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931-1939
105. Rinn JL, Rozowsky JS et al (2004) Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. Dev Cell 6(6):791-800
106. Rodvold KA, Rushing DA et al (1988) Doxorubicin clearance in the obese. J Clin Oncol 6(8):1321-1327
107. Saifi GM, Chandra HS (1999) An apparent excess of sex- and reproduction-related genes on the human X chromosome. Proc Biol Sci 266(1415):203-209
108. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
109. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006a) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (24):2542-2550
110. Sandler A, Gray R et al (2006b) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550
111. Schmidt R, Baumann F et al (2001) Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(3):193-200
112. Schuetz EG, Furuya KN et al (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275(2):1011-1018
113. Schwartz JB (2007) The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology. Clinical Pharmacology & Therapeutics 82, 87-96. doi:10.1038/sj.clpt.6100226
114. Sekine I, Yamamoto N et al (2008) Emerging ethnic differences in lung cancer therapy. Br J Cancer 99(11):1757-1762
115. Sheflin LG, Zhang W et al (2001) Androgen regulates the level and subcellular distribution of the AU-rich ribonucleic acid-binding protein HuR both in vitro and in vivo. Endocrinology 142(6):2361-2368
116. Shimada T, Yamazaki H et al (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414-423
117. Shinkai T, Eguchi K et al (1992) A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30(1):1-6
118. Singh S, Parulekar W et al (2005) Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23(4):850-856
119. Singhal SS, Saxena M et al (1992) Glutathione S-transferase of mouse liver: sex-related differences in the expression of various isozymes. Biochim Biophys Acta 1117(1):105
120. Socie G, Mary JY et al (2001) Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. Br J Haematol 113(1):194-201
121. Srivastava PK, Waxman DJ (1993) Sex-dependent expression and growth hormone regulation of class alpha and class mu glutathione S-transferase mRNAs in adult rat liver. Biochem J 294(Pt 1):159-165
122. Stahlberg N, Merino R et al (2005) Exploring hepatic hormone actions using a compilation of gene expression profiles. BMC Physiol 5(1):8
123. Stein BN, Petrelli NJ et al (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75(1):11-17
124. Sternberg CN, Davis ID et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061-1068
125. Stupp R, Mason WP et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
126. Sundseth SS, Waxman DJ (1992) Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. J Biol Chem 267(6):3915-3921
127. Temellini A, Castiglioni M et al (1995) Glutathione conjugation with 1-chloro-2,4-dinitrobenzene (CDNB): interindividual variability in human liver, lung, kidney and intestine. Int J Clin Pharmacol Ther 33(9):498-503
128. Ternant D, Henin E et al (2009) Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol 68(4):561-573
129. Timmer CJ, Sitsen JM et al (2000) Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38(6):461-474
130. Tortora R, Galeota Lanza A, Lampasi F, De Luca M, Tartaglione MT, Pacilio R, Di Constanzo GG (2011) Predictive factors for tumor control among hepatocellular carcinoma patients treated with sorafenib. Dig Liver Dis 43(Suppl 3):148
131. Tsalic M, Bar-Sela G et al (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol 26(1):103-106
132. Tsavaris N, Mylonakis N et al (1998) Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy. Oncol Rep 5(5):1147-1155
133. Tullis KM, Krebs CJ et al (2003) The regulator of sex-limitation gene, rsl, enforces male-specific liver gene expression by negative regulation. Endocrinology 144(5):1854-1860
134. Urien S, Barre J et al (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14(2):147-151
135. van Asperen J, van Tellingen O et al (1999a) Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. J Pharmacol Exp Ther 289(1):329-333
136. van Asperen J, van Tellingen O et al (1999b) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79(1):108-113
137. van der Veldt AAM, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJM, Haanen JBAG (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259-265
138. Veldhuis JD (1998) Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender. Growth Horm IGF Res 8(Suppl B):49-59
139. Veldhuis JD, Bowers CY (2003) Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 26(9):799-813
140. Veldhuis JD, Anderson SM et al (2001) Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res 11(Suppl A):S25-S37
141. Vokurka S, Bystricka E et al (2006) Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer 14(9):974-976
142. Wade JR, Kelman AW et al (1992) Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29(5):391-395
143. Wakelee HA, Wang W et al (2006) Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 1(5):441-446
144. Waxman DJ, Celenza JL (2003) Sexual dimorphism of hepatic gene expression: novel biological role of KRAB zinc finger repressors revealed. Genes Dev 17(21):2607-2613
145. Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76(2):215-228
146. Webster AC, Lee VW, et al (2006) Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 19(2): CD004290
147. Wei Q, Cheng L et al (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92(21):1764-1772
148. Wiesenfeld-Hallin Z (2005) Sex differences in pain perception. Gend Med 2(3):137-145
149. Wiwi CA, Gupte M et al (2004) Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice. Mol Endocrinol 18(8):1975-1987
150. Wolbold R, Klein K et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38(4):978-988
151. Yamamoto H, Sekine I et al (2008) Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology 75(3-4):169-174
152. Yamashita K, Mikami Y et al (2002) Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer Lett 188(1-2):231-236
153. Zhang HL, Ye DW, Shi GH, Yao XD, Zhang SL, Dai B, Shen YJ, Zhu Y, Yang BS (2009) Menstruations were altered by sorafenib in female patients with advanced renal cell carcinoma: the possible mechanism. Eur Urol 8(4):184